



Published in final edited form as:

Nature. 2013 March 28; 495(7442): 467–473. doi:10.1038/nature11922.

## Prion-like domain mutations in hnRNPs cause multisystem proteinopathy and ALS

Hong Joo Kim<sup>1,\*</sup>, Nam Chul Kim<sup>1,\*</sup>, Yong-Dong Wang<sup>2,\*</sup>, Emily A. Scarborough<sup>3,\*</sup>, Jennifer Moore<sup>1,\*</sup>, Zamia Diaz<sup>3,\*</sup>, Kyle S. MacLea<sup>4</sup>, Brian Freibaum<sup>1</sup>, Songqing Li<sup>1</sup>, Amandine Molliex<sup>1</sup>, Anderson P. Kanagaraj<sup>1</sup>, Robert Carter<sup>5</sup>, Kevin B. Boylan<sup>6</sup>, Aleksandra M. Wojtas<sup>6</sup>, Rosa Rademakers<sup>6</sup>, Jack L. Pinkus<sup>7</sup>, Steven A. Greenberg<sup>7</sup>, John Q. Trojanowski<sup>8</sup>, Bryan J. Traynor<sup>9</sup>, Bradley N. Smith<sup>8</sup>, Simon Topp<sup>10</sup>, Athina-Soragia Gkazi<sup>10</sup>, Jack Miller<sup>10</sup>, Christopher E. Shaw<sup>10</sup>, Michael Kottlors<sup>11</sup>, Janbernd Kirschner<sup>11</sup>, Alan Pestronk<sup>12</sup>, Yun R. Li<sup>13</sup>, Alice Flynn Ford<sup>3</sup>, Aaron D. Gitler<sup>14</sup>, Michael Benatar<sup>15</sup>, Oliver D. King<sup>16</sup>, Virginia E. Kimonis<sup>17</sup>, Eric D. Ross<sup>4</sup>, Conrad C. Wehl<sup>12</sup>, James Shorter<sup>3,†</sup>, and J. Paul Taylor<sup>1,†</sup>

<sup>1</sup>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38120, USA

<sup>2</sup>Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital, Memphis, TN 38120, USA

<sup>3</sup>Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>4</sup>Department of Biochemistry and Molecular Biology, Colorado State University; Fort Collins, CO 80523, USA

<sup>5</sup>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38120, USA

<sup>6</sup>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA

<sup>7</sup>Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

<sup>8</sup>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

<sup>†</sup>Correspondence: J. Paul Taylor, MD, Ph.D., [jpaul.taylor@stjude.org](mailto:jpaul.taylor@stjude.org) or James Shorter, Ph.D., [jshorter@mail.med.upenn.edu](mailto:jshorter@mail.med.upenn.edu).

\*These authors contributed equally to this work.

### Author Contributions

H.J.K., N.C.K., E.D.R., C.C.W., J.S. and J.P.T. designed experiments. H.J.K., N.C.K., E.A.S., J.M., Z.D., K.S.M., B.F., S.L., A.M., A.P.K., Y.R.L. and A.F.F. performed the experiments. K.B.B., A.M.W., R.R., J.L.P., S.A.G., J.Q.T., B.N.S., S.T., A.S.G., J.M., C.E.S., M.K., J.K., A.P., M.B. and V.E.K. provided patient clinical material, clinical evaluation, or evaluation of patient clinical material. H.J.K., N.C.K., Y.D.W., R.C., B.J.T., A.D.G., O.D.K., E.D.R., J.S. and J.P.T. contributed to data analysis. E.D.R., O.D.K. and C.C.W. contributed to manuscript preparation. H.J.K., J.S. and J.P.T. wrote the manuscript.

The authors declare no competing financial interests. Readers are welcome to comment on the online version of this article at [www.nature.com/nature](http://www.nature.com/nature).

<sup>9</sup>Neuromuscular Diseases Research Group, Laboratory of Neurogenetics, Porter Neuroscience Building, NIA, NIH, Bethesda, MD 20892, USA

<sup>10</sup>King's College London Centre for Neurodegeneration Research, Department of Clinical Neuroscience, Institute of Psychiatry, London SE5 8AF, UK

<sup>11</sup>Division of Neuropediatrics and Muscle Disorders, University Children's Hospital Freiburg, Freiburg, Germany

<sup>12</sup>Department of Neurology, Washington University School of Medicine, Saint Louis, MO 63110, USA

<sup>13</sup>Medical Scientist Training Program, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>14</sup>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA

<sup>15</sup>Neurology Department, University of Miami Miller School of Medicine, Miami, FL 33136, USA

<sup>16</sup>Boston Biomedical Research Institute, Watertown, MA 02472, USA

<sup>17</sup>Department of Pediatrics, Division of Genetics and Metabolism, University of California-Irvine, 2501 Hewitt Hall, Irvine, CA, 92696, USA

## Summary

Algorithms designed to identify canonical yeast prions predict that ~250 human proteins, including several RNA-binding proteins associated with neurodegenerative disease, harbor a distinctive prion-like domain (PrLD) enriched in uncharged polar amino acids and glycine. PrLDs in RNA-binding proteins are essential for the assembly of ribonucleoprotein granules. However, the interplay between human PrLD function and disease is not understood. Here, we define pathogenic mutations in PrLDs of hnRNPA2/B1 and hnRNPA1 in families with inherited degeneration affecting muscle, brain, motor neuron and bone, and a case of familial ALS. Wild-type hnRNPA2 and hnRNPA1 display an intrinsic tendency to assemble into self-seeding fibrils, which is exacerbated by the disease mutations. Indeed, the pathogenic mutations strengthen a 'steric zipper' motif in the PrLD, which accelerates formation of self-seeding fibrils that cross-seed polymerization of wild-type hnRNP. Importantly, the disease mutations promote excess incorporation of hnRNPA2 and hnRNPA1 into stress granules and drive the formation of cytoplasmic inclusions in animal models that recapitulate the human pathology. Thus, dysregulated polymerization caused by a potent mutant 'steric zipper' motif in a PrLD can initiate degenerative disease. Related proteins with PrLDs must be considered candidates for initiating and perhaps propagating proteinopathies of muscle, brain, motor neuron and bone.

---

Elucidating the genetic basis of rare, inherited diseases can provide valuable insights to the molecular pathogenesis of common diseases. Inclusion body myopathy with frontotemporal dementia (FTD), Paget's disease of bone and amyotrophic lateral sclerosis (ALS) (sometimes called "IBMPFD/ALS") is a rare disorder characterized by progressive degeneration of muscle, brain, motor neurons and bone accompanied by prominent TDP-43 pathology<sup>1</sup>. Patients with this rare, inherited syndrome experience features of IBM, FTD, ALS or PDB indistinguishable from familial and sporadic cases of these disorders, and the

disease may manifest in multiple tissues in the same patient<sup>1,2</sup>. Recently the name “multisystem proteinopathy” (MSP) has been adopted to reflect the expanding phenotype and prominent proteinaceous pathology that characterizes this syndrome. Some, but not all, cases of MSP are caused by mutations in the *VCP* gene<sup>3</sup>, which encodes the AAA+-ATPase VCP, a ubiquitin-dependent segregase. The discovery that *VCP* mutations cause MSP led to the subsequent discovery of pathogenic *VCP* mutations in more common diseases such as sporadic or familial forms of ALS<sup>2</sup>, FTD<sup>4</sup>, IBM<sup>5</sup>, and PDB<sup>6</sup>. These rare MSP families represent a unique opportunity to identify fundamental molecular defects shared among age-related diseases; thus it is highly desirable to identify additional genetic mutations responsible for this syndrome.

## Identification of a pathogenic mutation in hnRNPA2B1 in *VCP*-negative MSP

We identified a family (family 1) with dominantly inherited degeneration affecting muscle, bone, brain, and motor neurons that was clinically indistinguishable from prior families we have seen with *VCP*-related MSP (Fig. 1a and Supplementary Fig. 1 and Table 1). Sequencing the entire *VCP* gene including introns and exons in affected patients revealed no synonymous or non-synonymous variants. Genetic analysis of this family by exome sequencing and linkage analysis in parallel (Supplementary Fig. 1) identified a single novel variant (c.869/905A>T, p.D290V/302V) that co-segregated with disease and impacted the gene encoding hnRNPA2B1, a ubiquitously expressed RNA-binding protein (Fig. 1a). hnRNPA2B1 is expressed as two alternatively spliced isoforms: A2 and B1. The shorter hnRNPA2, which lacks 12 amino acids in the N-terminal region, is the major isoform accounting for ~90% of the protein in most tissues. This mutation substitutes valine for an aspartate residue that is evolutionarily conserved (Fig. 1d) and also centered in a motif that is conserved in multiple human paralogs in the hnRNP A/B family (Fig 1f and Supplementary Fig. 3).

## Identification of pathogenic mutations in hnRNPA1

Additional validation of the pathogenicity of the hnRNPA2B1 mutation came from the analysis of family 2. The clinical features of this family with *VCP*-negative MSP have been previously described<sup>7</sup>. To identify the culprit mutation we took the same strategy as for family 1 (Supplementary Fig. 2 and Table 2). This analysis identified 5 novel SNVs and 1 indel that co-segregated with disease. Of these, a mutation in hnRNPA1 (c.785/941A>T, p.D262V/314V) stood out because it was the only variant that impacted a conserved residue, it was predicted to be deleterious, and hnRNPA1 is highly expressed in affected tissues (Fig. 1b and Supplementary Fig. 2). Moreover, this mutation in hnRNPA1 was identical to that found in hnRNPA2B1 in family 1, creating a substitution of valine for a highly conserved aspartate residue that is centered in a motif conserved in multiple human paralogs the hnRNP A/B family (Fig. 1e–f and Supplementary Fig. 3). Subsequent to the identification of these MSP-causing mutations we screened the exomes of 212 familial ALS cases for sequence variants affecting hnRNPA2B1 or hnRNPA1. In one dominantly inherited case in which known ALS genes were formally excluded we identified a mutation (c.784/940G>A;

p.D262/314N) impacting the identical, conserved aspartate residue in hnRNP1 (Fig. 1c, e–f).

Identification of disease mutations in hnRNP2B1 and hnRNP1 was intriguing for 3 reasons. First, hnRNP2/B1 and hnRNP1 directly interact with TDP-43 and function cooperatively to regulate RNA metabolism<sup>8</sup>. Second, an unbiased genetic screen previously identified fly homologs of TDP-43, hnRNP2B1 and hnRNP1 as suppressors of VCP-related degeneration in a *Drosophila* model of MSP<sup>9</sup> (Supplementary Fig. 3). Finally, hnRNP2/B1 was previously implicated in neurodegenerative disease. Specifically, hnRNP2/B1 is sequestered in RNA foci in the fragile X-associated tremor ataxia syndrome (FXTAS)<sup>10</sup>, binds the expanded rCGG repeats that underlie this disease<sup>11,12</sup>, and is a genetic modifier in a *Drosophila* model of FXTAS<sup>11,12</sup>.

### hnRNP2B1 and hnRNP1 pathology in MSP

Muscle biopsies from patients II5 (family 1) and IV9 (family 2) showed atrophic fibers, central nuclei and rimmed vacuoles characteristic of IBM (Supplementary Fig. 4a–c). Whereas in normal muscle hnRNP2B1 and hnRNP1 are exclusively nuclear (Fig. 2a, e and Supplementary Fig. 4d), analysis of muscle tissue from patient II5 (family 1) showed that hnRNP2B1 cleared from many nuclei and accumulated in cytoplasmic inclusions in ~10% of fibers (Fig. 2b and Supplementary Fig. 4e). Muscle from this patient also exhibited TDP-43 pathology consisting of nuclear clearance and cytoplasmic inclusions, consistent with prior observations in VCP-related and sporadic IBM (Fig. 2j and Supplementary Fig. 4p)<sup>13</sup>. Interestingly, hnRNP2B1 pathology was also observed in VCP-related and sporadic IBM (Fig. 2c, d and Supplementary Fig. 4h, i).

Analysis of muscle from patient IV9 (family 2) revealed nuclear clearance and cytoplasmic inclusions of hnRNP1 also in ~10% of fibers (Fig. 2f and Supplementary Fig. 4j). hnRNP2B1 and TDP-43 pathology were also observed in the muscle biopsy from patient IV9 (family 2) (Fig. 2h, k and Supplementary Fig. 4f, g). Moreover, hnRNP1 pathology was also observed in VCP-related and sporadic IBM (Fig. 2g and data not shown). Therefore, regardless of etiology we have found hnRNP2B1, hnRNP1 and TDP-43 pathology in sporadic and familial IBM. Pathological redistribution of hnRNP2B1, hnRNP1, and TDP-43 was not observed in other types of muscle disease (Supplementary Fig. 4q). FUS/TLS pathology was not observed in these cases, thus pathological redistribution does not affect all hnRNPs. Double staining revealed that fibers with TDP-43 pathology typically also exhibited hnRNP2B1 and hnRNP1 pathology (Fig. 2m–p and Supplementary Fig. 4g, k). In these instances there was often partial co-localization of TDP-43, hnRNP2B1 and hnRNP1. We also observed limited immunopositivity for ubiquitin and p62 (Supplementary Fig. 4l–o).

### Disease mutations impact a prion-like domain in hnRNP2/B1 and hnRNP1

hnRNP2/B1 and hnRNP1 each have C-terminal, glycine-rich domains that are essential for activity and mediate interaction with TDP-43<sup>8</sup>. FoldIndex predicts these domains to be

intrinsically unfolded (Fig. 3a–b). Interestingly, these low complexity domains have amino acid composition similar to that of yeast prion domains. Indeed, an algorithm devised by Alberti *et al.*<sup>14</sup> predicted that the C-terminal regions of hnRNPA2 (residues 185–341) and hnRNPA1 (residues 186–320) are prion-like (Fig. 3a–d), whereas these domains narrowly missed the cutoff for prion propensity according to the Toombs *et al.* algorithm<sup>15</sup>. Interestingly, similar “prion-like domains” (PrLDs) are present in many hnRNPs, including TDP-43 and FUS (Supplementary Fig. 5 and Table 3). The disease-causing mutations fall at the center of the predicted PrLD, and, according to both algorithms, are expected to enhance prion-like behavior (Fig. 3a–b).

We also examined hnRNPA2/B1 and hnRNPA1 with ZipperDB, a structure-based threading algorithm, which scores 6-amino acid segments for their propensity to form 2 self-complementary beta strands termed “steric zippers” that form the spine of amyloid fibrils<sup>16</sup>. Hexapeptides with Rosetta energy lower than  $-23\text{kcal/mol}$  are predicted to form steric zippers, with lower energy predicting higher amyloidogenicity. ZipperDB predicted that disease mutations increase the potency of steric zipper motifs present in the PrLDs of hnRNPA2/B1 and hnRNPA1 (Fig. 3c–f). This analysis is discussed in greater detail in Supplementary Fig. 6. Taken together, multiple algorithms predict that the PrLDs of hnRNPA2/B1 and hnRNPA1 are intrinsically disordered, but poised to access higher order self-templating structures. Notably, the disease mutations are centered within these PrLDs and predicted to promote transition to an ordered structure.

## hnRNPA2 and hnRNPA1 are intrinsically fibrillization-prone and disease mutations accelerate fibrillization

We directly tested the predictions that (i) hnRNPA2 and hnRNPA1 are prone to fibrillization and (ii) this property is enhanced by disease-causing mutations. First, we experimentally assessed the ZipperDB prediction for the impact of disease mutations on steric zipper motifs found in hnRNPA2/B1 and hnRNPA1. Remarkably, the synthetic mutant hexapeptides of hnRNPA2/B1-D290V (NYNVFG) and hnRNPA1-D262V (SYNVFG) rapidly assembled into amyloid fibrils, as shown by thioflavin-T fluorescence and electron microscopy (EM), whereas the corresponding wild-type peptides did not even after several weeks (Fig. 4a–d). Thus, the disease mutations in hnRNPA2/B1 and hnRNPA1 generate highly amyloidogenic hexapeptides precisely as predicted. The more potent steric zippers that result from disease mutations are likely to be significant for two reasons. First, introduction of similarly potent steric zippers is sufficient to force fibril formation even in model proteins that do not ordinarily fibrillize<sup>17</sup>. Second, in hnRNPA1 and hnRNPA2 these potent steric zippers are centered in the intrinsically disordered PrLD and are thus available to make intermolecular contacts and drive fibril formation.

We next assessed the fibrillization propensity of full-length proteins. We purified bacterially expressed, GST-tagged wild-type and mutant hnRNPA2 and hnRNPA1 as soluble proteins under native conditions and assessed fibrillization by sedimentation analysis and EM. Wild-type hnRNPA2 and hnRNPA1 were both intrinsically aggregation prone with a lag phase of  $\sim 4\text{h}$  (Fig. 4e, g). EM revealed that wild-type hnRNPA2 and hnRNPA1 form fibrils (Fig. 4f, h). The pronounced lag suggests that a critical rate-limiting step in hnRNPA2 and hnRNPA1

fibrillization is nucleation. Indeed, a small quantity (5% wt/wt) of preformed hnRNPA2 or hnRNPA1 fibrils greatly accelerated the assembly of hnRNPA2 or hnRNPA1, respectively (Supplementary Fig. 7a, e). By contrast, preformed hnRNPA2 fibrils did not seed assembly of hnRNPA1 (Supplementary Fig. 7e). Likewise, preformed hnRNPA1 fibrils did not seed assembly of hnRNPA2 (Supplementary Fig. 7a). Thus, wild-type hnRNPA1 and hnRNPA2 spontaneously form self-seeding fibrils.

Importantly, the disease mutations greatly accelerated hnRNPA2 and hnRNPA1 fibrillization (Fig. 4e–h). In all cases, the lag phase was curtailed and fibrillization was well advanced while the wild-type protein remained in lag phase. Thus, the disease mutations directly promote nucleation of hnRNPA2 and hnRNPA1 into fibrils. Moreover, fibrils formed by hnRNPA2-D290V, hnRNPA1-D262V, and hnRNPA1-D262N not only seeded their own assembly (Supplementary Fig. 7b, f, g), but also promoted fibrillization of their respective wild-type counterparts (Supplementary Fig. 7d, i). Neither hnRNPA2-D290V fibrils nor hnRNPA1-D262V fibrils seeded the assembly of TDP-43, another RNA-binding protein with a PrLD.

Finally, we assessed the importance of the steric zipper motifs in fibrillization. We deleted the steric zipper residues 287–292 from hnRNPA2 and 259–264 from hnRNPA1 and assessed fibrillization in vitro. Importantly, neither hnRNPA2<sup>287–292</sup> nor hnRNPA1<sup>259–264</sup> formed fibrils (Fig. 4e, g), even after 24h with agitation. Moreover, hnRNPA2<sup>287–292</sup> did not fibrillize when seeded by fibrils of wild-type or mutant hnRNPA2 (Supplementary Fig. 7c), nor did hnRNPA1<sup>259–264</sup> fibrillize when seeded by fibrils of wild-type or mutant hnRNPA1 (Supplementary Fig. 7h). Thus, residues 287–292 of hnRNPA2 and 259–264 of hnRNPA1 are critical for spontaneous and seeded fibrillization of the full-length protein. Collectively, these findings indicate that steric zipper motifs centered in the PrLDs of wild-type hnRNPA2 and hnRNPA1 are critical to their intrinsic tendency to fibrillize and that disease mutations introduce more potent steric zippers, which accelerate nucleation and polymerization (Supplementary Fig. 6)

## The PrLD of mutant hnRNPA2/B1 supports prion activity in yeast

Yeast prion proteins are generally modular, meaning that prion domains from one protein can be transferred to another, while retaining prion activity<sup>18</sup>. To determine whether the PrLD of hnRNPA2/B1 could support prion activity in yeast, we replaced the Sup35 nucleation domain (residues 3–40) with the core PrLD (residues 261–303) from either wild-type or mutant hnRNPA2/B1 and expressed these fusion proteins as the sole copies of Sup35 in the cell. Prion formation was detected by monitoring nonsense suppression of the *ade2-1* allele and verified by monitoring a series of prion-defining criteria, including curability with guanidine, transferability with cytoduction and sensitivity to expression levels (detailed in Supplementary Fig. 8). This analysis showed that the hnRNPA2/B1 core PrLD can substitute for the Sup35 nucleation domain in supporting prion formation, and that the D290V mutation specifically promotes the nucleation activity. Moreover, full-length hnRNPA1 and A2 form cytoplasmic aggregates and are toxic in yeast (Supplementary Fig. 9).



## Disease mutations enhance recruitment of hnRNPA2 and hnRNPA1 to stress granules

Remarkably, the PrLDs in hnRNPA2B1 and hnRNPA1 correspond to the “low complexity sequences” found in various hnRNPs (including TDP-43 and FUS) that are essential determinants of RNA granule assembly<sup>19</sup>. Stress granules (SGs) are cytoplasmic ribonucleoprotein (RNP) granules composed of repressed translation complexes<sup>20,21</sup>. TDP-43 and FUS are recruited to SGs and this is enhanced by disease mutations<sup>20</sup>. Thus, we hypothesized that hnRNPA2B1 and hnRNPA1 would be recruited to SGs and that this would be enhanced by disease mutations. To test this, we first examined the subcellular localization of endogenous hnRNPA2/B1 in HeLa cells before and after SG induction with arsenite. At baseline, endogenous hnRNPA2/B1 was localized exclusively to nuclei (Supplementary Fig. 10). Following arsenite treatment hnRNPA2/B1 relocalized to eIF4G–positive cytoplasmic puncta, showing the recruitment of endogenous hnRNPA2/B1 to SGs (Supplementary Fig. 10).

To examine the impact of disease mutations, we expressed Flag-tagged versions of wild-type and mutant hnRNPA2. There was significantly greater incorporation of mutant hnRNPA2 into constitutive SGs than wild-type hnRNPA2 (Fig. 5a). Moreover, following arsenite treatment mutant hnRNPA2 was incorporated into SGs more rapidly than wild-type hnRNPA2, although by 30 min their degree of incorporation was similar (Fig. 5b). Both wild-type and mutant hnRNPA2 formed high molecular weight species that accumulated in the detergent-insoluble fraction (Fig. 5c). Similar to the kinetics of SG incorporation, mutant hnRNPA2 accumulated as high molecular weight species more rapidly than wild-type hnRNPA2, although by 30 min their accumulation was comparable (Fig. 5c). Similar results were obtained upon examination of endogenous hnRNPA1 as well as exogenous wild-type and mutant hnRNPA1 (Supplementary Fig. 11). Interestingly, hnRNPA2-positive and hnRNPA1-positive SGs were also immunopositive for TDP-43 (Supplementary Fig. 12). We also generated fibroblast cell lines from patients II4 and II6 (family 1). In these cells endogenous mutant hnRNPA2 accumulated in constitutive SGs that were immunopositive for eIF4G in addition to TDP-43 and VCP (Supplementary Fig. 13).

## Mutant hnRNPs accumulate in pathological inclusions in vivo

We generated transgenic *Drosophila* expressing wild-type or mutant forms of human hnRNPA2 and hnRNPA1, as well as wild-type or mutant forms of the fly homolog Hrb98DE (Supplementary Figs. 14 and 15). Expression of wild-type hnRNPA2 in *Drosophila* indirect flight muscle led to mild degeneration affecting the rostral portion of several muscles, whereas expression of hnRNPA2-D290V caused severe degeneration that affected all muscles (Fig. 6a). Importantly, flies over-expressing hnRNPA2<sup>287–292</sup>, in which the hexapeptide (NYNDFG) in the PrLD was deleted, had virtually normal muscles (Fig. 6a). This result indicates that the severe toxicity found in flies over-expressing mutant hnRNPA2 requires the presence of this potent steric zipper motif.

Immunohistochemical analysis showed that wild-type hnRNPA2 localized appropriately to nuclei, as did hnRNPA2<sup>287–292</sup>, whereas hnRNPA2-D290V largely accumulated in

cytoplasmic inclusions (Fig. 6b). We observed a correlation between cytoplasmic inclusion formation and solubility of hnRNPA2. Specifically, mutant hnRNPA2-D290V protein was largely recovered from the detergent-insoluble fraction, whereas wild-type hnRNPA2 and hnRNPA2<sup>287-292</sup> proteins were mostly found in the detergent-soluble fraction (Fig. 6c-d). Thus, the degree of muscle degeneration in flies expressing hnRNPA2 correlates with the extent of cytoplasmic inclusions and with hnRNPA2 solubility. Entirely consistent results were obtained upon expression of wild-type and mutant versions of hnRNPA1 and Hrb98DE (Supplementary Fig. 15).

Lastly, we evaluated the impact of the disease mutation on hnRNPA2 cellular localization in mammalian muscle. We electroporated mouse tibialis anterior with plasmid expressing Flag-tagged versions of wild-type or mutant hnRNPA2. Wild-type hnRNPA2 was localized appropriately within nuclei, whereas mutant hnRNPA2-D290V was excluded from nuclei and accumulated in cytoplasmic inclusions (Supplementary Fig. 16) highly reminiscent of the pathology seen in MSP patients.

## Discussion

Polymerization of PrLDs underlies the orderly, regulated phase transition that drives assembly of nonmembrane-bound organelles including RNA granules, which serve as "reaction crucibles" in which many aspects of RNA metabolism occur<sup>22</sup>. Disease mutations introduce more potent steric zippers into the PrLDs of hnRNPA2 and hnRNPA1, dysregulating and accelerating nucleation and polymerization, altering the dynamics of RNA granule assembly, which likely has adverse consequences for RNA metabolism. In addition to hnRNPA2 and hnRNPA1, at least four other RNA-binding proteins that harbor PrLDs (TDP-43, FUS, EWSR1, and TAF15) accumulate in disease pathology<sup>23</sup>. By analogy to hnRNPA2/B1 and hnRNPA1, we speculate that these and perhaps other PrLD-containing proteins contribute to the initiation or propagation of disease by a similar mechanism. Indeed, ~250 human proteins are predicted to harbor PrLDs, many of which are RNA-binding proteins (Supplementary Fig. 5 and Table 3), and must be considered candidates for contributing to degenerative disease.

Thus, disease could ensue from unregulated polymerization initiated spontaneously by PrLDs upon environmental stress, by a mutation impacting the PrLD, or by a mutation impacting another factor (e.g. VCP) that regulates the ribonucleoprotein granule assembly with altered metabolism of RNA as a consequence.

Notably, diseases associated with pathological inclusions of PrLD-containing proteins frequently show "spreading" pathology, in which cellular degeneration with intracellular inclusions starts in one epicenter and subsequently spreads to neighboring tissue<sup>24</sup>. While not directly addressed here, this study suggests that cell-to-cell transmission of a self-templating conformer could contribute to the spreading pathology that is characteristic of these diseases.

The discovery of *VCP* mutations in MSP<sup>1</sup> led to the subsequent discovery of pathogenic *VCP* mutations in sporadic or familial forms of ALS<sup>2</sup>, FTD<sup>4</sup>, IBM<sup>5</sup>, and PDB<sup>6</sup>. Therefore,



subsequent to the discovery of mutations in hnRNPA2B1 and hnRNPA1 underlying MSP, we screened 212 familial ALS cases and identified a pathogenic hnRNPA1 mutation in one family, as described above. As this manuscript was being assembled for publication we completed screening of 305 sporadic ALS cases and identified a nonsynonymous variant in hnRNPA1 (c.800/956A>G, p.N267/319S) in one classic, late-onset case in which mutations in known ALS genes had been excluded (Supplementary Figure 17). Although not definitive, this variant is likely pathogenic since it is centered in the core PrLD and introduces a potent steric zipper similar to that introduced by D262V/N mutations. The frequency of hnRNPA2B1 and hnRNPA1 mutations in ALS, and the possibility that mutations in these genes underlie some sporadic and familial forms of FTD, IBM, and PDB, is will be important to address in the future.

## Methods

### Patients

Patients were examined by M.B. and J.P.T. except where indicated. Review Board (IRB) of the University of Miami approved the study protocol and all participants provided written informed consent.

### Exome capture and next-generation sequencing

Exome enrichment of 3 µg of genomic DNA was performed by using the Agilent SureSelect Human All Exon kit capture library (G3362 for 5 DNA samples from family 1 and G3370 for 5 DNA samples from family 2) according to the manufacturer's protocol (SureSelect Human All Exon Illumina Paired-End protocol version 1.0.1). The capture library, containing regions totaling approximately 38 Mb (G3362) or 50 Mb (G3370), is designed to target all human exons in the NCBI consensus coding sequence (CCDS) database. Captured DNAs were sequenced on an Illumina GAIx sequencer (Illumina, San Diego, CA) with 76 bp (family 1) or 100 bp (family 2) paired-end reads. At least 2 lanes of sequencing data were collected for each sample to generate sufficient coverage. Image analyses and base calling were performed by using the Illumina Genome Analyzer Pipeline software (GAPipeline version 1.5 or higher) with default parameters. Reads were aligned to a human reference sequence (UCSC assembly hg19, NCBI build 37) and genotypes were called at all positions at which there were high-quality sequence bases (Phred-like score Q25 or greater) at minimum coverage of 8, using CLC Genomics Workbench v4.5.1 (CLC Bio, Cambridge, MA). For each sample, more than 50% of at least 100 million reads were uniquely mapped to the targeted human exon regions to give mean depth of coverage of 123. Under such coverage, approximately 94% of targeted regions were covered by 5 reads or more, and more than 85% were covered by more than 20 reads (Supplementary Fig. 1). To identify the pathogenic mutations, we performed a series of filtering steps (Supplementary Fig. 1). We first discarded the variants that did not change the amino acid sequence. We then generated a list of variants that are present in affected individuals but absent in nonaffected individuals. Variants previously reported in dbSNP132 were excluded, as the causative variants were uncommon and unlikely to be registered in the SNP database. The variants were further filtered by using the in-house database (a collection of variants from whole-exome sequencing of more than 625 individuals) by a similar methodology. Finally Sanger

sequencing was performed on DNAs of 3 additional members (both affected and nonaffected) from each family to exclude the nonpathogenic mutations. Presence of mutations was confirmed in all candidate disease-causing variants by Sanger sequencing.

### Linkage analysis

Eight DNA samples (parents and 6 siblings) from family 1 were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 (Santa Clara, CA, USA). SNP genotype calls were performed according to the standard Affymetrix protocols. A subset of SNPs chosen on the basis of heterozygosity was used for linkage analysis, using dChip Software ([www.biosun1.harvard.edu/complab/dchip/](http://www.biosun1.harvard.edu/complab/dchip/)) under Parametric Linkage Analysis and a dominant model with 99% penetrance in heterozygotes and a disease allele frequency of 0.001. Five genomic segments with a size greater than 100 kb, at least 20 SNP markers, and an LOD score greater than 0 are shown in Supplementary Fig. 1.

### Generation of phylogram for hnRNP A/B gene family

TBPH of *D. melanogaster* was used to BLAST against the RefSeq protein database including species of *M. musculus*, *D. melanogaster*, *A. gambiae*, *H. sapiens*, *D. Rerio* (zebrafish), *C. elegans* and *G. gallus* (jungle fowl). The top 100 sequences (according to BLAST E-Values) were obtained. Sequences sharing more than 98% similarity were filtered by UCLUST<sup>25</sup> because they likely represent alternatively spliced variants of the same genes. Eighty-one sequences remaining after this process were aligned using the MAFFT multiple sequence alignment program<sup>26</sup>. The DNA coding sequences of all proteins were extracted and threaded onto the protein sequences to form an in-frame codon alignment. Squint<sup>27</sup> was used to extract the DNA coding alignment of the two RRM domains present in each protein using the protein alignment as a guide. Phylogenetic trees of the codon alignment including twenty-one genes from only human and drosophila were generated using the genetic algorithm-based GARLI<sup>28</sup> method.

### Constructs

cDNAs encoding human hnRNPA2 (accession number NM\_002137.2) or hnRNPA1 (accession number NM\_002136.1) in the plasmid pCMV6-XL5 were obtained from OriGene. A Flag epitope tag was added to the 5'-end of hnRNPA2 or hnRNPA1 by PCR. The cDNAs were then subcloned into a pcDNA 3.1 plasmid, using restriction sites *EcoRI* and *XhoI*, creating pcDNA 3.1/Flag-hnRNPA2 or hnRNPA1. cDNAs encoding drosophila Hrb98DE (accession number NM\_170373.1) was obtained from Drosophila Genomics Research Center. Missense mutations of hnRNPA2 (hnRNPA2 D290V), hnRNPA1 (hnRNPA1 D252V) and drosophila Hrb98DE (Hrb98DE D302V) were generated by site-directed mutagenesis. Sequence analysis was conducted on all plasmid constructs.

### Antibodies

The following commercial antibodies were used in this study: mouse monoclonal anti-hnRNPA2/B1 antibodies (EF-67 and DP3B3) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); rabbit polyclonal anti-TDP-43 antibody (Protein Tech Group, Chicago, IL); anti-eIF4G antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); anti-hnRNPA1 antibody (Cell

Signaling Technology, Inc., Danvers, MA); anti-VCP antibody (Epitomics, Inc., Burlingame, CA); anti-Flag M2 antibody (Sigma). Anti-hnRNPA1 (4B10 and 9H10) antibodies were generous gifts from Dr. G. Dreyfuss. Validation of these antibodies is shown in Supplementary Fig. 18.

### Cell culture and transfection

HEK293 cells and HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1% L-glutamate. Human fibroblasts were grown in DMEM: nutrient mixture F-12 (DMEM/F12) supplemented with 20% FBS, 1% penicillin/streptomycin, and 1% L-glutamate. Cells were transfected using Lipofectamine LTX with Plus Reagent (Invitrogen), according to the manufacturer's instructions.

### RNAi

siRNAs against hnRNPA2/B1 were ordered from Santa Cruz Biotechnology (sc-43841, target sequences: CAGUCCGUAAGCUCUUUAtt, GGAUGGCUAUAAGGGUAtt and GGAUCAUGGUGUAAUAAGAtt) and Dharmacon (ON-TARGETplus SMARTpool, Human HNRPA2B1 (3181), target sequences: CGGUGGAAUUUCGGACCA, GCUGUUUGUUGGCGAAUU, GGAGAGUAGUUGAGCCAAA and GAGGAGGAUCUGAUGGAUA). Control siRNAs were ordered from Dharmacon (ON-TARGETplus Non-targeting siRNA #1 (# D-001810-01-05). HeLa cells were transfected in 6-well plates with Lipofectamine RNAiMax (Invitrogen) according to the manufacturer's protocol and collected after 48 and 72 h.

### Immunofluorescence studies

Cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS), permeabilized with 0.5% Triton X-100 in PBS for 10 min, blocked with 5% goat serum in PBS for 30 min, and incubated with primary antibody for 2 h at room temperature or overnight at 4 °C. Primary antibodies were visualized with secondary antibodies conjugated with Alexa Fluor 488 and Alexa Fluor 594 (Molecular Probes, Invitrogen), and nuclei were detected using DAPI. Stained cells were examined using a confocal microscope (Zeiss LSM 510 NLO Meta) with Zeiss ZEN software.

### Solubility and biochemical analyses

Sequential extractions were performed to examine the solubility profile of hnRNPA2/B1. Cells were washed twice with PBS, lysed in cold RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% Na deoxycholate, 0.1% SDS, and 1 mM EDTA), and sonicated. Cell lysates were cleared by centrifugation at 100,000 g for 30 min at 4 °C to generate RIPA-soluble samples. To prevent carry-overs, the resulting pellets were washed twice with PBS (i.e., resonicated and recentrifuged). Only supernatants from the first centrifugation were analyzed. RIPA-insoluble pellets were then extracted with urea buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, pH 8.5), sonicated, and centrifuged at 100,000 g for 30 min at 22 °C. Protease inhibitors were added to all buffers before use.

Protein concentration was determined by the bicinchoninic acid method (Pierce), and proteins were resolved by NuPAGE Novex 4–12% Bis-Tris Gel (Invitrogen).

### ***In vivo* electroporation of mice**

All animal work was performed with approval of the St. Jude Children's Research Hospital Committee on Animal Care. Mice were anesthetized and the skin overlying the tibialis anterior (TA) muscle was shaved, and the animals were injected with endotoxin-free Flag-hnRNPA2 wild-type or D290V mutant diluted in sterile PBS to a volume of 50  $\mu$ l by using a 0.5 ml syringe fitted with a 29-gauge needle. Two-needle array electrodes (BTX, San Diego, California) were inserted into the muscle immediately after DNA delivery for electroporation. The distance between the electrodes was 5 mm, and the array was inserted longitudinally relative to the muscle fibers. *In vivo* electroporation parameters were as follows: voltage, 75 V; pulse length, 50-ms; number of pulses, 6; pulse interval, 200 ms; desired field strength, 200 V/cm, given by a BTX ECM830 Electro Square Porator. After 7 days of recovery, mice were processed for immunofluorescence analysis.

### **Muscle histochemistry and immunohistochemistry**

Human samples were processed for routine histochemical analysis as previously described<sup>13</sup>. For skeletal muscle immunohistochemistry, isolated skeletal muscle was mounted by using tragacanth gum and quick frozen in liquid nitrogen-cooled 2-methylbutane. Sections (8  $\mu$ M) were placed on slides and fixed in 4% paraformaldehyde for 5 min and then ice-cold acetone for 5 min. Sections were blocked in PNB (Perkin Elmer) for 1 h and then incubated overnight in primary antibody diluted in PNB. After serial washes in 1X PBS, slides were incubated in secondary antibody diluted in PNB for 2 h. Sections were mounted with MOWIOL containing DAPI. Specimens were examined using a fluorescent microscope (80i upright; Nikon) and charge-coupled device camera (EZ monochrome; Roper Industries) with deconvolution software analysis (NIS Elements; Nikon). Nonfluorescent images were taken with a 5-megapixel color charge-coupled device (Nikon). Image processing and analysis were performed with NIS Elements 4.0 software and Photoshop CS3 (Adobe).

### **Yeast strains, media, and plasmids**

Yeast cells were grown in rich media (YPD) or in synthetic media lacking uracil and containing 2% glucose (SD/-Ura), raffinose (SRaf/-Ura), or galactose (SGal/-Ura). The TDP-43 and FUS yeast expression constructs have been previously described<sup>29–31</sup>. WT and IBMPFD-associated mutant HNRNPA2B1 and HNRNPA1 Gateway<sup>®</sup> entry clones were generated by PCR, incorporating the flanking Gateway attB1 and attB2 sites along with a Kozak consensus sequence. Resulting PCR products were shuttled into pDONR221, using a Gateway BR reaction. Two versions of each entry clone (with or without stop codon) were then used in LR reactions with pAG416Gal-ccdB, pAG426Gal-ccdB, pAG416Gal-ccdB-GFP, or pAG426Gal-ccdB-GFP<sup>32</sup> to generate the CEN and 2  $\mu$ m untagged or YFP-fusion constructs. Primer sequences are available upon request. To prevent unwanted recombination events owing to unstable repetitive sequences in the HNRNPA2B1 and HNRNPA1 DNA sequence, we propagated plasmids in SURE-2 or STBL-3 *E. coli* at 30 °C.

For testing the phenotype of WT and IBMFPD-associated mutant hnRNPA2 as Sup35-fusion proteins, PCR was used to amplify amino acids 261–303 of hnRNPA2 and insert it into Sup35 in the place of amino acids 3–40. The resulting PCR products were cotransformed with BamHI/HindIII-cut pJ526 (from Dan Masison, National Institutes of Health; Ref. <sup>33</sup>) into strain 780-1D (*MAT $\alpha$  kar1-1 SUQ5 ade2-1 his3 202 leu2 1 trp1 63 ura3-52 sup35::KanMX*) containing the *SUP35* maintainer plasmid pJ533 (from Dan Masison; Ref. <sup>34</sup>). Transformants were selected on medium lacking leucine, and then transferred to 5-fluoroorotic acid-containing medium to select for loss of pJ533. Sequences were confirmed by DNA sequencing. Overexpression plasmids were generated by PCR amplification, restriction digest, and cloning into compatible sites in pKT24 (from Kim Taylor, NABI, Rockville, MD), which contains a *GAL1* promoter, as previously described <sup>35</sup>.

### Yeast transformation and spotting assays

Yeast procedures were performed according to standard protocols<sup>36</sup>. The PEG/lithium acetate method was used to transform yeast with plasmid DNA<sup>37</sup>. For spotting assays, yeast cells were grown overnight at 30 °C in liquid media containing raffinose (SRaf/-Ura) until they reached log or mid-log phase. Cultures were then normalized for OD 600, serially diluted, spotted onto synthetic solid media containing glucose or galactose lacking uracil, and grown at 30 °C for 2–3 days. HNRNPA2B1-Sup35 fusions were tested for prion formation and for stability and curability of the Ade+ phenotype as previously described<sup>35</sup>. Cytoductions were performed as previously described<sup>38</sup>. The recipient strain was YER746 (*MAT $\alpha$  kar1-1 SUQ5 ade2-1 his3 leu2 trp1 ura3 arg1::HIS3 sup35::KanMx*), carrying plasmid pER697 (URA3), which expresses the D290V A2-Sup35 fusion from the *SUP35* promoter.

### Fluorescence microscopy for yeast

For fluorescence microscopy experiments, single colony isolates of yeast strains were grown to mid-log phase in SRaf/-Ura media at 30 °C. Cultures were spun down and resuspended in the same volume of SGal/-Ura to induce expression of the HNRNPA2B1 or HNRNPA1 constructs. Cultures were induced with galactose for 4–6 h and processed for microscopy. Images were obtained by an Olympus IX70 inverted microscope and a Photometrics CoolSnap HQ 12-bit CCD camera. Z-stacks of several fields were collected for each strain. The images were deblurred using a nearest neighbor algorithm in the Deltavision Softworx software and representative cells were chosen.

### Hexapeptide assembly

The A2 WT (NYNDFG), A2 D290V (NYNVFG), A1 WT (SYNDFG) and A1 D262V (SYNVFG) hexapeptides were synthesized at the Keck Biotechnology Resource Laboratory at Yale University School of Medicine. A1 peptides were dissolved at 1 mM and A2 peptides at 5 mM in 150 mM KCl, 40 mM HEPES-KOH, pH 7.4, and 1 mM DTT and used immediately for assembly reactions. Fiber assembly reactions were monitored at  $\lambda_{ex/em}$  440/482 nm, in the presence of 25  $\mu$ M Thioflavin-T (ThT), at room temperature on a Tecan

Safire<sup>2</sup> or Tecan Infinite M1000 plate reader. Alternatively, reactions were processed for electron microscopy as for the full-length hnRNPs (see below).

### hnRNP purification

WT and mutant hnRNPA2 or hnRNPA1 were expressed and purified from *Escherichia coli* as GST-tagged proteins. Expression constructs were generated in pDuet to contain a TEV-cleavable site, resulting in a GST-TEV-hnRNP construct<sup>30,31</sup>. GST-TEV-hnRNP was overexpressed in *E. coli* BL21 (DE3) RIL cells (Agilent) and purified under native conditions using a glutathione-sepharose column (GE) according to the manufacturer's instructions. Proteins were eluted from the glutathione sepharose with assembly buffer (AB: 40 mM HEPES-KOH, 150 mM KCl, 5% Glycerol, 20 mM glutathione, pH 7.4). Protein was centrifuged for 10 min at 16,100 g, and supernatant was separated from pellet to remove any protein aggregates. Protein concentration was determined by Bradford assay (Bio-Rad) in comparison to BSA standards.

### *In vitro* fibril formation assay

For GST-tagged protein, aggregation was initiated by adding TEV protease (Invitrogen) to GST-TEV-hnRNPA2 (3 $\mu$ M) or GST-TEV-hnRNPA1 (5 $\mu$ M) in AB. Aggregation reactions were incubated at 25°C for 0–12 h with or without agitation at 1200 rpm in an Eppendorf Thermomixer. For self-seeded and cross-seeded reactions, hnRNPA2, hnRNPA2 D290V, hnRNPA1, or hnRNPA1 D262V fibrils were assembled at 5 $\mu$ M for 24h with agitation at 1400rpm in AB. These preformed fibrils then used to seed (5% wt/wt) the assembly of hnRNPA2 (2.5 $\mu$ M), hnRNPA2 D290V (2.5 $\mu$ M), hnRNPA1 (5 $\mu$ M), hnRNPA1 D262V (5 $\mu$ M), or hnRNPA1 D262N (5 $\mu$ M) in AB as indicated. Here, assembly reactions were agitated at 1,200rpm at 25°C. For hnRNPA2 cross-seeding reactions the amount of preformed fibrils added was increased to 10% wt/wt and reactions were not agitated. In hnRNPA1 cross-seeding reactions, preformed fibrils were briefly sonicated to fragment fibrils prior to addition to the assembly reaction. For hnRNPA1 cross-seeding reactions the amount of preformed fibrils added was 5% wt/wt and reactions were not agitated. For sedimentation analysis, samples were centrifuged at 16,100 g for 10 min at 25 °C. Pellet fractions were resolved by SDS-PAGE and stained with Coomassie Blue. The amount of protein in the pellet fraction was determined by densitometry in comparison to known amounts of hnRNP. For electron microscopy (EM) of *in vitro* aggregation reactions, samples (10  $\mu$ l) were adsorbed onto glow-discharged 300-mesh Formvar/carboncoated copper grid (Electron Microscopy Sciences) and stained with 2% (w/v) aqueous uranyl acetate. Excess liquid was removed, and grids were allowed to air dry. Samples were viewed by a JEOL 1010 transmission electron microscope.

### Fly stocks and culture

The hnRNPA2 wild-type and D290V cDNAs were subcloned into pUASTattB plasmid, using restriction sites *Eco*RI and *Xho*I, creating pUASTattB/hnRNPA2 WT or D290V. Hrb98DE wild-type and D302V were subcloned into pUASTattB plasmid using *Not*I and *Xho*I sites. Flies carrying pUASTattB transgenes were generated by a standard injection and  $\phi$ C31 integrase-mediated transgenesis technique. To express a transgene in muscles, MHC-



GAL4 was used (from Dr. Guillermo Marqués). All *Drosophila* stocks were maintained in a 25 °C incubator with a 12 h day/night cycle.

### Adult fly muscle preparation and immunohistochemistry

Adult flies were embedded in a drop of OCT compound (Sakura Finetek) on a slide glass, frozen with liquid nitrogen, and bisected sagittally by a razor blade. After fixing with 4% paraformaldehyde in PBS, hemithoraces were stained by Texas Red-X-Phalloidin (Invitrogen) and DAPI according to manufacturer's instructions. Stained hemithoraces were mounted in 80% glycerol, and the musculature was examined by DMIRE2 (Leica, 10X). For hnRNPA2 staining, hemithoraces were permeabilized with PBS containing 0.2% Triton X-100 and stained with anti-hnRNPA2/B1 (EF-67) antibody (Santa Cruz Biotechnology) and Alexa 488 conjugated secondary antibody (Invitrogen). Stained muscle fibers were dissected and mounted in Fluormount-G (Southern Biotech) and imaged with a Marianas confocal microscope (Zeiss, 63X)

### Fly western blotting

Thoraces of adult flies were prepared and ground in PBS containing 0.2% Triton X-100. After adding SDS sample buffer, samples were boiled for 5 min and analyzed by the standard Western blotting method provided by Odyssey system (LI-COR) with 4–12% NuPAGE Bis-Tris gel (Invitrogen) and anti-hnRNPA2/B1 antibody (Santa Cruz, 1:1000).

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgements

We thank the patients whose participation made this work possible. We thank the St. Jude Pediatric Cancer Genome Project and Jinghui Zhang in particular for providing access to control sequencing data. We thank Cinzia Gellera, Bob Baloh, Matt Harms, Sabine Krause, Gideon Dreyfuss and Tim Cundy for sharing reagents. We thank Sandra Donkervoort and Steven Mumm for coordinating samples, and Ana Taylor for editorial assistance. JPT was supported by ALSAC, the Packard Foundation and NIH NS053825; JPT and MB were supported by the ALS Association; JQT was supported by NIH AG032953; JS was supported by NIH DP2OD002177 and NS067354 and the Ellison Medical Foundation; EDR was supported by NSF MCB-1023771.

### References


1. Nalbandian A, et al. The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. *J Mol Neurosci*. 2011; 45:522–531. [PubMed: 21892620]
2. Johnson JO, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. *Neuron*. 2010; 68:857–864. [PubMed: 21145000]
3. Watts GD, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nat Genet*. 2004; 36:377–381. [PubMed: 15034582]
4. Neumann M, Tolnay M, Mackenzie IR. The molecular basis of frontotemporal dementia. *Expert Rev Mol Med*. 2009; 11:e23. [PubMed: 19638255]
5. Shi Z, et al. Characterization of the Asian myopathy patients with VCP mutations. *Eur J Neurol*. 2011

6. Chung PY, et al. Indications for a genetic association of a VCP polymorphism with the pathogenesis of sporadic Paget's disease of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms. *Mol Genet Metab.* 2011; 103:287–292. [PubMed: 21501964]
7. Kottlors M, et al. Late-onset autosomal dominant limb girdle muscular dystrophy and Paget's disease of bone unlinked to the VCP gene locus. *J Neurol Sci.* 2010; 291:79–85. [PubMed: 20116073]
8. Buratti E, et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. *J Biol Chem.* 2005; 280:37572–37584. [PubMed: 16157593]
9. Ritson GP, et al. TDP-43 mediates degeneration in a novel *Drosophila* model of disease caused by mutations in VCP/p97. *J Neurosci.* 2010; 30:7729–7739. [PubMed: 20519548]
10. Iwahashi CK, et al. Protein composition of the intranuclear inclusions of FXTAS. *Brain.* 2006; 129:256–271. [PubMed: 16246864]
11. Sofola OA, et al. RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a *Drosophila* model of FXTAS. *Neuron.* 2007; 55:565–571. [PubMed: 17698010]
12. Jin P, et al. Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a *Drosophila* model of fragile X tremor/ataxia syndrome. *Neuron.* 2007; 55:556–564. [PubMed: 17698009]
13. Salajegheh M, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. *Muscle Nerve.* 2009; 40:19–31. [PubMed: 19533646]
14. Alberti S, Halfmann R, King O, Kapila A, Lindquist S. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. *Cell.* 2009; 137:146–158. [PubMed: 19345193]
15. Toombs JA, McCarty BR, Ross ED. Compositional determinants of prion formation in yeast. *Mol Cell Biol.* 2010; 30:319–332. [PubMed: 19884345]
16. Goldschmidt L, Teng PK, Riek R, Eisenberg D. Identifying the amyloids, proteins capable of forming amyloid-like fibrils. *Proc Natl Acad Sci U S A.* 2010; 107:3487–3492. [PubMed: 20133726]
17. Teng PK, Eisenberg D. Short protein segments can drive a non-fibrillizing protein into the amyloid state. *Protein Eng Des Sel.* 2009; 22:531–536. [PubMed: 19602569]
18. Li L, Lindquist S. Creating a protein-based element of inheritance. *Science.* 2000; 287:661–664. [PubMed: 10650001]
19. Kato M, et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. *Cell.* 2012; 149:753–767. [PubMed: 22579281]
20. Wolozin B. Regulated protein aggregation: stress granules and neurodegeneration. *Mol Neurodegener.* 2012; 7:56. [PubMed: 23164372]
21. Buchan JR, Parker R. Eukaryotic stress granules: the ins and outs of translation. *Mol Cell.* 2009; 36:932–941. [PubMed: 20064460]
22. Weber SC, Brangwynne CP. Getting RNA and protein in phase. *Cell.* 2012; 149:1188–1191. [PubMed: 22682242]
23. Neumann M, et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. *Brain.* 2011; 134:2595–2609. [PubMed: 21856723]
24. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. Prion-like disorders: blurring the divide between transmissibility and infectivity. *J Cell Sci.* 2010; 123:1191–1201. [PubMed: 20356930]

## References for Methods


25. Edgar RC. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics.* 2010; 26:2460–2461. [PubMed: 20709691]
26. Katoh K, Asimenos G, Toh H. Multiple alignment of DNA sequences with MAFFT. *Methods Mol Biol.* 2009; 537:39–64. [PubMed: 19378139]

27. Goode MG, Rodrigo AG. SQUINT: a multiple alignment program and editor. *Bioinformatics*. 2007; 23:1553–1555. [PubMed: 17485434]
28. Zwickl DJ. Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion. Ph. D. dissertation, The University of Texas at Austin. 2006
29. Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. *Proc Natl Acad Sci U S A*. 2008; 105:6439–6444. [PubMed: 18434538]
30. Johnson BS, et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. *J Biol Chem*. 2009; 284:20329–20339. [PubMed: 19465477]
31. Sun Z, et al. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. *PLoS Biol*. 2011; 9:e1000614. [PubMed: 21541367]
32. Alberti S, Gitler AD, Lindquist S. A suite of Gateway((R)) cloning vectors for high-throughput genetic analysis in *Saccharomyces cerevisiae*. *Yeast (Chichester, England)*. 2007; 24:913–919.
33. Ross ED, Edskes HK, Terry MJ, Wickner RB. Primary sequence independence for prion formation. *Proc. Natl. Acad. Sci. USA*. 2005; 102:12825–12830. [PubMed: 16123127]
34. Song Y, et al. Role for Hsp70 chaperone in *Saccharomyces cerevisiae* prion seed replication. *Eukaryot. Cell*. 2005; 4:289–297. [PubMed: 15701791]
35. Ross CD, McCarty BM, Hamilton M, Ben-Hur A, Ross ED. A promiscuous prion: Efficient induction of [URE3] prion formation by heterologous prion domains. *Genetics*. 2009; 183:929–940. [PubMed: 19752212]
36. Guthrie C, Fink GR. *Methods in Ezymology: Guide to Yeast Genetics and Molecular and Cell Biology*. Academic Press. 2002; 169
37. Ito H, Fukuda Y, Murata K, Kimura A. Transformation of intact yeast cells treated with alkali cations. *J Bacteriol*. 1983; 153:163–168. [PubMed: 6336730]
38. Ross ED, Edskes HK, Terry MJ, Wickner RB. Primary sequence independence for prion formation. *Proc Natl Acad Sci U S A*. 2005; 102:12825–12830. [PubMed: 16123127]



**Figure 1. Identification of novel disease mutations in MSP and ALS**

**a.** Family 1 pedigree indicating individuals affected by dementia, myopathy, PDB, and ALS. The causative mutation was p.D290V/302V in hnRNPA2B1. **b.** Family 2 pedigree indicating individuals affected by myopathy and PDB. The causative mutation was p.D262/314V in hnRNPA1. **c.** The pedigree of a family with ALS. The causative mutation was p.D262/314N in hnRNPA1. **d–e.** Sequence alignment of hnRNPA2/B1 (**d**) and hnRNPA1 (**e**) orthologs showing evolutionary conservation of the mutated aspartate and surrounding residues. **f.** Sequence alignment of 4 human paralogs of the hnRNP A/B family in which the disease-affected residue and surrounding residues are highly conserved.




**Figure 2. Cytoplasmic pathology of hnRNPA2/B1 and hnRNPA1**

**a–d.** Immunohistochemical analysis of hnRNPA2/B1 (red) in normal muscle (**a**), muscle biopsy from patient II5 from family 1 (**b**), a patient with MSP caused by *VCP* mutation (R155H) (**c**), a patient with sporadic IBM (**d**). hnRNPA2/B1 (red) was cleared from DAPI-stained nuclei (blue) and accumulated in cytoplasmic inclusions (**b–d**). **e–g.** Immunohistochemical analysis of hnRNPA1 (red) in a normal muscle (**e**), a muscle biopsy from patient IV9 from family 2 (**f**), a patient with MSP caused by *VCP* mutation (R155H) (**g**). hnRNPA1 was cleared from nuclei and accumulated in cytoplasmic inclusions (**f, g**). **h.**




In muscle tissue from patient IV9 (family 2), hnRNPA2/B1 was cleared from nuclei and accumulated in cytoplasmic inclusions. (**i–l**) Immunohistochemical analysis of TDP-43 (red) in a normal muscle (**i**), muscle biopsy from patient II5 from family 1 (**j**), muscle biopsy from patient IV9 from family 2 (**k**), and a patient with MSP caused by *VCP* mutation (R155H) (**l**). TDP-43 (red) was cleared from DAPI-stained nuclei (blue) and accumulated in cytoplasmic inclusions (**j–l**). **m–p**. Immunohistochemical analysis of hnRNPA2/B1 and TDP-43 colocalization in a patient with sporadic IBM. DAPI (**m**), TDP-43 (**n**), hnRNPA2/B1 (**o**) and merged images (**p**) are shown. hnRNPA2/B1 (red) and TDP-43 (green) were cleared from nuclei (arrowheads) in an atrophic muscle fiber, but found in nuclei of neighboring unaffected fibers (arrows). Scale bars represent 50  $\mu$ M.





**Figure 3. The disease mutations impact a PrLD in hnRNPA2/B1 and hnRNPA1**  
**a–b.** FoldIndex predicts an extended intrinsically unfolded regions (grey curve less than zero) in the C-termini of hnRNPA2 and hnRNPA1. These regions were also predicted to be prion-like according to the algorithm of Alberti *et al*<sup>14</sup> (red curve less than zero), and narrowly missed the cutoff for the prion propensity by algorithm of Toombs *et al*<sup>15</sup> (green curve below the dashed green line). All curves represent averages of 41 consecutive windows of 41 amino acids, corresponding to the criteria of Toombs *et al*<sup>15</sup>. The disease mutations were predicted to make these domains more prionogenic (insets). **c–d.** ZipperDB detected 6-amino-acid stretches (underlined in **e–f**) within the core PrLDs for which the disease mutations increased the predicted amyloid fibril-forming potential beyond the Rosetta threshold. **e–f.** Domain architecture of hnRNPA2 and hnRNPA1 shows the RNA-recognition motifs (RRM1 and RRM2), the C-terminal glycine-rich domain, and an M9 nuclear localization signal. The PrLDs are centered in the C-terminal glycine-rich domain. Highly similar predictions were made for the minor isoforms of hnRNPA2B1 (hnRNPA1) and hnRNPA1 (hnRNPA1 isoform b).



**Figure 4. Disease mutations accelerate hnRNP2 and hnRNP1 fibrillization**

**a.** Synthetic hexapeptides A2 wild-type (NYNDFG) or mutant (NYNVFG) were incubated at 25°C for 2h. Fibrillization was monitored by ThT fluorescence. **b.** EM of A2 wild-type or mutant hexapeptides after 10min at 25°C. Bar, 0.1 $\mu$ m. **c–d.** Fibrillization analysis of A1 wild-type (SYNDFG) or mutant (SYNVFG) as in (a–b). **e.** Full-length hnRNP2 WT, hnRNP2 D290V, or hnRNP2<sup>287–292</sup> was incubated at 25 °C with agitation for 0–12h. At various times, the amount of aggregated hnRNP2 was determined. Values represent means  $\pm$  SEM (n=3). **f.** EM of hnRNP2 fibrillization reactions after 0, 4, and 12h at 25°C. Note


the absence of fibers after 4h for hnRNPA2 wild-type. Bar, 0.5 $\mu$ m. **g-h**. Fibrillization of full-length hnRNPA1 wild-type, hnRNPA1-D262V, hnRNPA1-D262N, or hnRNPA1<sup>259-264</sup> monitored as in (**e, f**).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 5. hnRNPA2 recruitment to SGs is accelerated by disease mutation**

**a–b.** HeLa cells were transfected with Flag-tagged wild-type or mutant hnRNPA2 and stained with anti-Flag (green), anti-eIF4G (red), and DAPI (blue). Arrows indicate hnRNPA2- and eIF4G-positive SGs. **b.** HeLa cells were transfected as in (a), treated with 0.5 mM sodium arsenite for the indicated time, and immunostained as in (a). The percentage of cells displaying hnRNPA2-positive SGs at indicated time points following treatment with arsenite cells are plotted. Data represent mean ± SEM (n=3) (\*\*\*)  $P < 0.001$ . **c.** HeLa cells

were transfected and stimulated as in **(b)**, and sequentially extracted with RIPA and urea buffer. Immunoblotting was conducted with anti-Flag and anti-TDP-43 antibodies.


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





**Figure 6. Mutant hnRNPA2 forms cytoplasmic inclusions in *Drosophila***

**a.** Adult flies were dissected to expose the dorsal longitudinal indirect flight muscle and stained with Texas Red-phalloidin (red), and DAPI (blue). Flies expressing human wild-type hnRNPA2 under control of the MHC-GAL4 driver showed mild degeneration, whereas flies expressing mutant human hnRNPA2 show severe degeneration affecting all muscles. Flies expressing hnRNPA2<sup>287-292</sup> show muscle histology similar to flies expressing wild-type hnRNPA2. **b.** wild-type hnRNPA2 localizes exclusively to nuclei, whereas hnRNPA2-D290V also accumulates extensively in cytoplasmic inclusions. hnRNPA2<sup>287-292</sup> localizes



exclusively to nuclei. **c.** Thoraces of adult flies were dissected and sequential extractions were performed to examine the solubility profile of hnRNPA2. **d.** Quantification of the blot shown in **c.** Data represent mean  $\pm$  SEM (n=3) (\* $P < 0.05$ , \*\*\* $P < 0.001$  by two-way ANOVA with Bonferroni's post hoc test).